WFRF:(Heckman B)
Search: WFRF:(Heckman B) > HOX gene expression...
- 5 of 17
- Previous record
- Next record
- To hitlist
- Kontro, M (author)
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
- Article/chapterEnglish2017
Publisher, publication year, extent ...
- 2016-08-08
- Springer Science and Business Media LLC,2017
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-310826
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-310826URI
- https://doi.org/10.1038/leu.2016.222DOI
- http://kipublications.ki.se/Default.aspx?queryparsed=id:135217503URI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. To identify robust biomarkers for BCL-2 inhibitor sensitivity, we evaluated the ex vivo sensitivity of fresh leukemic cells from 73 diagnosed and relapsed/refractory AML patients, and then comprehensively assessed whether the responses correlated to specific mutations or gene expression signatures. Compared with samples from healthy donor controls (nonsensitive) and chronic lymphocytic leukemia (CLL) patients (highly sensitive), AML samples exhibited variable responses to BCL-2 inhibition. Strongest CLL-like responses were observed in 15% of the AML patient samples, whereas 32% were resistant, and the remaining exhibited intermediate responses to venetoclax. BCL-2 inhibitor sensitivity was associated with genetic aberrations in chromatin modifiers, WT1 and IDH1/IDH2. A striking selective overexpression of specific HOXA and HOXB gene transcripts were detected in highly BCL-2 inhibitor sensitive samples. Ex vivo responses to venetoclax showed significant inverse correlation to β2-microglobulin expression and to a lesser degree to BCL-XL and BAX expression. As new therapy options for AML are urgently needed, the specific HOX gene expression pattern can potentially be used as a biomarker to identify venetoclax-sensitive AML patients for clinical trials.Leukemia advance online publication, 2 September 2016; doi:10.1038/leu.2016.222.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Kumar, A (author)
- Majumder, M M (author)
- Eldfors, S (author)
- Parsons, A (author)
- Pemovska, T (author)
- Saarela, J (author)
- Yadav, B (author)
- Malani, D (author)
- Fløisand, Y (author)
- Höglund, MartinUppsala universitet,Hematologi(Swepub:uu)martinhl (author)
- Remes, K (author)
- Gjertsen, B T (author)
- Kallioniemi, OKarolinska Institutet (author)
- Wennerberg, K (author)
- Heckman, C A (author)
- Porkka, K (author)
- Uppsala universitetHematologi (creator_code:org_t)
Related titles
- In:Leukemia: Springer Science and Business Media LLC31:2, s. 301-3090887-69241476-5551
Internet link
- 5 of 17
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Kontro, M
- Kumar, A
- Majumder, M M
- Eldfors, S
- Parsons, A
- Pemovska, T
- show more...
- Saarela, J
- Yadav, B
- Malani, D
- Fløisand, Y
- Höglund, Martin
- Remes, K
- Gjertsen, B T
- Kallioniemi, O
- Wennerberg, K
- Heckman, C A
- Porkka, K
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
- Articles in the publication
- Leukemia
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
